214 related articles for article (PubMed ID: 32710489)
1. Genotype-phenotype correlation at codon 1740 of SETD2.
Rabin R; Radmanesh A; Glass IA; Dobyns WB; Aldinger KA; Shieh JT; Romoser S; Bombei H; Dowsett L; Trapane P; Bernat JA; Baker J; Mendelsohn NJ; Popp B; Siekmeyer M; Sorge I; Sansbury FH; Watts P; Foulds NC; Burton J; Hoganson G; Hurst JA; Menzies L; Osio D; Kerecuk L; Cobben JM; Jizi K; Jacquemont S; Bélanger SA; Löhner K; Veenstra-Knol HE; Lemmink HH; Keller-Ramey J; Wentzensen IM; Punj S; McWalter K; Lenberg J; Ellsworth KA; Radtke K; Akbarian S; Pappas J
Am J Med Genet A; 2020 Sep; 182(9):2037-2048. PubMed ID: 32710489
[TBL] [Abstract][Full Text] [Related]
2. Epigenotype-genotype-phenotype correlations in SETD1A and SETD2 chromatin disorders.
Lee S; Menzies L; Hay E; Ochoa E; Docquier F; Rodger F; Deshpande C; Foulds NC; Jacquemont S; Jizi K; Kiep H; Kraus A; Löhner K; Morrison PJ; Popp B; Richardson R; van Haeringen A; Martin E; Toribio A; Li F; Jones WD; Sansbury FH; Maher ER
Hum Mol Genet; 2023 Nov; 32(22):3123-3134. PubMed ID: 37166351
[TBL] [Abstract][Full Text] [Related]
3. Clinical Heterogeneity and Different Phenotypes in Patients with
Parra A; Rabin R; Pappas J; Pascual P; Cazalla M; Arias P; Gallego-Zazo N; Santana A; Arroyo I; Artigas M; Pachajoa H; Alanay Y; Akgun-Dogan O; Ruaud L; Couque N; Levy J; Porras-Hurtado GL; Santos-Simarro F; Ballesta-Martinez MJ; Guillén-Navarro E; Muñoz-Hernández H; Nevado J; Spanish OverGrowth Registry Initiative ; Tenorio-Castano J; Lapunzina P
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372360
[TBL] [Abstract][Full Text] [Related]
4. Mutation pattern and genotype-phenotype correlations of SETD2 in neurodevelopmental disorders.
Chen M; Quan Y; Duan G; Wu H; Bai T; Wang Y; Zhou S; Ou J; Shen Y; Hu Z; Xia K; Guo H
Eur J Med Genet; 2021 May; 64(5):104200. PubMed ID: 33766796
[TBL] [Abstract][Full Text] [Related]
5. Two novel cases expanding the phenotype of SETD2-related overgrowth syndrome.
van Rij MC; Hollink IHIM; Terhal PA; Kant SG; Ruivenkamp C; van Haeringen A; Kievit JA; van Belzen MJ
Am J Med Genet A; 2018 May; 176(5):1212-1215. PubMed ID: 29681085
[TBL] [Abstract][Full Text] [Related]
6. A Case of Luscan-Lumish Syndrome: Possible Involvement of Enhanced GH Signaling.
Suda K; Fukuoka H; Iguchi G; Kanie K; Fujita Y; Odake Y; Matsumoto R; Bando H; Ito H; Takahashi M; Chihara K; Nagai H; Narumi S; Hasegawa T; Ogawa W; Takahashi Y
J Clin Endocrinol Metab; 2021 Mar; 106(3):718-723. PubMed ID: 33248444
[TBL] [Abstract][Full Text] [Related]
7. Dual Chromatin and Cytoskeletal Remodeling by SETD2.
Park IY; Powell RT; Tripathi DN; Dere R; Ho TH; Blasius TL; Chiang YC; Davis IJ; Fahey CC; Hacker KE; Verhey KJ; Bedford MT; Jonasch E; Rathmell WK; Walker CL
Cell; 2016 Aug; 166(4):950-962. PubMed ID: 27518565
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic features of luscan-lumish syndrome associated with a novel de novo variant of
Zhang Y; Zhang H; Wu W; Wang D; Lv Y; Zhao D; Wang L; Liu Y; Zhang K
Front Genet; 2023; 14():1081391. PubMed ID: 36777730
[No Abstract] [Full Text] [Related]
9. Cellular and molecular functions of SETD2 in the central nervous system.
Mitchell B; Thor S; Piper M
J Cell Sci; 2023 Nov; 136(21):. PubMed ID: 37921122
[TBL] [Abstract][Full Text] [Related]
10. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
11. A novel
Wu Y; Liu F; Wan R; Jiao B
Front Genet; 2023; 14():1153284. PubMed ID: 37025455
[No Abstract] [Full Text] [Related]
12. A New Chromatin-Cytoskeleton Link in Cancer.
Giaccia AJ
Mol Cancer Res; 2016 Dec; 14(12):1173-1175. PubMed ID: 27528705
[TBL] [Abstract][Full Text] [Related]
13. Novel USP9X variant associated with syndromic intellectual disability in a female: A case study and review.
Meira JGC; Magalhães BS; Ferreira IBB; Tavares DF; Kobayashi GS; Leão EKEA
Am J Med Genet A; 2021 May; 185(5):1569-1574. PubMed ID: 33638286
[TBL] [Abstract][Full Text] [Related]
14. SETD2 related overgrowth syndrome: Presentation of four new patients and review of the literature.
Marzin P; Rondeau S; Aldinger KA; Alessandri JL; Isidor B; Heron D; Keren B; Dobyns WB; Cormier-Daire V
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):509-518. PubMed ID: 31643139
[TBL] [Abstract][Full Text] [Related]
15. Mutations in SETD2 cause a novel overgrowth condition.
Luscan A; Laurendeau I; Malan V; Francannet C; Odent S; Giuliano F; Lacombe D; Touraine R; Vidaud M; Pasmant E; Cormier-Daire V
J Med Genet; 2014 Aug; 51(8):512-7. PubMed ID: 24852293
[TBL] [Abstract][Full Text] [Related]
16. Novel unconventional variants expand the allelic spectrum of OPHN1 gene.
Nuovo S; Brankovic V; Caputi C; Casella A; Nigro V; Leuzzi V; Valente EM
Am J Med Genet A; 2021 May; 185(5):1575-1581. PubMed ID: 33638601
[TBL] [Abstract][Full Text] [Related]
17. Molecular determinants for α-tubulin methylation by SETD2.
Kearns S; Mason FM; Rathmell WK; Park IY; Walker C; Verhey KJ; Cianfrocco MA
J Biol Chem; 2021 Jul; 297(1):100898. PubMed ID: 34157286
[TBL] [Abstract][Full Text] [Related]
18.
Tlemsani C; Luscan A; Leulliot N; Bieth E; Afenjar A; Baujat G; Doco-Fenzy M; Goldenberg A; Lacombe D; Lambert L; Odent S; Pasche J; Sigaudy S; Buffet A; Violle-Poirsier C; Briand-Suleau A; Laurendeau I; Chin M; Saugier-Veber P; Vidaud D; Cormier-Daire V; Vidaud M; Pasmant E; Burglen L
J Med Genet; 2016 Nov; 53(11):743-751. PubMed ID: 27317772
[TBL] [Abstract][Full Text] [Related]
19. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
